HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Skip Over Navigation Links
Staff banner

Staff Profile: Andre Pilon

Andre M. Pilon, Ph.D.
Andre M. Pilon, Ph.D.

Program Management (Contractor)

Division of Pre-Clinical Innovation

National Center for Advancing Translational Sciences

National Institutes of Health

E-mail Andre M. Pilon

Biography

Andre M. Pilon works on the portfolio management and strategic operations team that manages NCATS’ Therapeutics for Rare and Neglected Diseases (TRND) program, a diverse and highly collaborative research and development effort. Pilon completed doctoral and postdoctoral research on the molecular underpinnings of red blood cell development and disorders at the National Human Genome Research Institute (NHGRI) under the mentorship of David M. Bodine, Ph.D. Before joining TRND, Pilon served as a policy and education fellow with detail appointments in the NHGRI Office of Policy, Communications and Education; the American Society of Human Genetics; the American Association for Cancer Research; and the NIH Office of Legislative Policy and Analysis.

Pilon received a B.A. in chemistry-biochemistry from Colby College and a Ph.D. in biochemistry and molecular genetics from the George Washington University Medical Center, where he participated in a joint research program with NIH.

Professional Interests

Pilon is an enthusiastic communicator. His work involves helping diverse audiences of fellow researchers, policymakers, business leaders and the public understand NCATS’ exceptional research programs. He manages the solicitation of collaborative projects for TRND and develops outreach and communications messages. Pilon is keenly interested in implementing operational efficiency. He continuously seeks to develop and refine strategies to solicit, evaluate and initiate new collaborative research opportunities, including identifying potential synergies with other NCATS and NIH programs.

Selected Publications

  1. NIH TRND program: successes in preclinical therapeutic development.